Abstract |
We evaluated the capacity of the cationic lipid based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. We immunized Balb/c mice with varying doses (0.4-50 microg) of plasmid DNA (pDNA) encoding the P. yoelii circumsporozoite protein (PyCSP), either in a homologous DNA/ DNA regimen ( D-D) or a heterologous prime-boost DNA-poxvirus regimen (D-V). At the lowest pDNA doses, Vaxfectin substantially enhanced IFA titers, ELISPOT frequencies, and protective efficacy. Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin may improve their potency in human clinical trials.
|
Authors | Martha Sedegah, William O Rogers, Arnel Belmonte, Maria Belmonte, Glenna Banania, Noelle Patterson, Marilyn Ferrari, David C Kaslow, Daniel J Carucci, Thomas L Richie, Denise L Doolan |
Journal | Vaccine
(Vaccine)
Vol. 24
Issue 11
Pg. 1921-7
(Mar 10 2006)
ISSN: 0264-410X [Print] Netherlands |
PMID | 16298024
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Adjuvants, Immunologic
- Antibodies, Protozoan
- Malaria Vaccines
- Phosphatidylethanolamines
- Protozoan Proteins
- Vaccines, DNA
- circumsporozoite protein, Protozoan
- vaxfectin
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Animals
- Antibodies, Protozoan
(blood)
- Female
- Fluorescent Antibody Technique, Indirect
- Humans
- Immunization, Secondary
- Lymphocytes
(immunology)
- Malaria
(prevention & control)
- Malaria Vaccines
(administration & dosage, genetics, immunology)
- Mice
- Mice, Inbred BALB C
- Phosphatidylethanolamines
(administration & dosage, pharmacology)
- Plasmodium yoelii
(immunology)
- Protozoan Proteins
(genetics, immunology)
- Vaccines, DNA
(administration & dosage, genetics, immunology)
- Vaccinia virus
(genetics)
|